Wir sind mit live! Mehr erfahren
35,39 USD
-0,56
1,56 %
Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT
Vor Börsenbeginn
Nachbörslich
35,25
-0,14
0,4 %
1 Tag
-1,56 %
5 Tage
-1,34 %
1 Monat
9,13 %
3 Monate
-24,7 %
6 Monate
-5,88 %
Seit Jahresbeginn
-21,6 %
1 Jahr
16,8 %
5 Jahre
-78,31 %
10 Jahre
-1,01 %
 

Profil: Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.

Mitarbeiter: 3.485

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 44,4 %
Neutral 50 %
Negativ 5,6 %
Positiv
Zacks Investment Research
vor 4 Tagen
Is This the Right Time to Retain Omnicell Stock in Your Portfolio?
OMCL raises its 2026 earnings outlook on cost discipline and efficiency, but rising memory costs and delayed Titan XT adoption pose challenges.
Is This the Right Time to Retain Omnicell Stock in Your Portfolio?
Neutral
Business Wire
vor 8 Tagen
Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026.
Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026
Positiv
Zacks Investment Research
vor 15 Tagen
Omnicell (OMCL) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Omnicell (OMCL) is a Top-Ranked Value Stock: Should You Buy?
Positiv
Zacks Investment Research
letzten Monat
Here's Why Omnicell (OMCL) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Omnicell (OMCL) is a Strong Value Stock
Neutral
PRNewsWire
letzten Monat
TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations
Integration brings serialized product verification and traceability directly into medication receiving workflows, intended to enable more efficient pharmacy operations without separate compliance processes. BOSTON, Sept.
TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations
Neutral
Business Wire
letzten Monat
Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference.
Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference
Positiv
Zacks Investment Research
letzten Monat
Why Omnicell (OMCL) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Omnicell (OMCL) is a Top Value Stock for the Long-Term
Neutral
The Motley Fool
letzten Monat
Omnicell President Sells 6,753 Shares
The disposal comprised 6,753 shares representing a total transaction value of ~$250,000. The transaction reduced the insider's direct equity holdings by 4%.
Omnicell President Sells 6,753 Shares
Positiv
Zacks Investment Research
vor 2 Monaten
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins.
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
Negativ
Zacks Investment Research
vor 2 Monaten
OMCL Falls 20.1% in a Month as Booking and Margin Risks Build
Omnicell's 20.1% monthly slide reflects booking uncertainty, margin pressure and refresh-cycle risks despite a higher 2026 profit outlook.
OMCL Falls 20.1% in a Month as Booking and Margin Risks Build
Kursdiagramme mit Lightweight Charts™ umgesetzt